FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:758-760 February 16, 2006 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Gogas, H. PubMed Citation

Adjuvant treatment for patients after resection of high-risk and regionally metastatic melanoma remains suboptimal. Despite the Food and Drug Administration's approval of high-dose interferon alfa-2b, the substantial toxicity of the therapy and the fact that its benefit is limited to 20 to 30 percent of patients at risk have hindered its general acceptance.

Attempts to identify patients who benefit from adjuvant treatment with interferon alfa-2b have been disappointing to date. Although analyses of individual studies suggest that the benefit of high-dose interferon alfa-2b might be restricted to certain subgroups of patients, on the basis of the number of melanoma-involved lymph . . . [Full Text of this Article]

Source Information

From Beth Israel Deaconess Medical Center, Boston.

This article has been cited by other articles:

• Madhunapantula, S. V., Desai, D., Sharma, A., Huh, S. J., Amin, S., Robertson, G. P. (2008). PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Molecular Cancer Therapeutics 7: 1297-1308 [Abstract] [Full Text]  
• Zimmerer, J. M., Lehman, A. M., Ruppert, A. S., Noble, C. W., Olencki, T., Walker, M. J., Kendra, K., Carson, W. E. III (2008). IFN-{alpha}-2b-Induced Signal Transduction and Gene Regulation in Patient Peripheral Blood Mononuclear Cells Is Not Enhanced by a Dose Increase from 5 to 10 Megaunits/m2. Clin. Cancer Res. 14: 1438-1445 [Abstract] [Full Text]  
• Kottke, T., Sanchez-Perez, L., Diaz, R. M., Thompson, J., Chong, H., Harrington, K., Calderwood, S. K., Pulido, J., Georgopoulos, N., Selby, P., Melcher, A., Vile, R. (2007). Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. Cancer Res. 67: 11970-11979 [Abstract] [Full Text]  
• BRACCI, L., PROIETTI, E., BELARDELLI, F. (2007). IFN-{alpha} and Novel Strategies of Combination Therapy for Cancer. Ann. N. Y. Acad. Sci. 1112: 256-268 [Abstract] [Full Text]  
• Madhunapantula, S. V., Sharma, A., Robertson, G. P. (2007). PRAS40 Deregulates Apoptosis in Malignant Melanoma. Cancer Res. 67: 3626-3636 [Abstract] [Full Text]  
• Voltz, R. (2007). Can antibodies in serum predict the presence of microscopic tumors?. Neurology 68: 887-888 [Full Text]  
• Sanchez-Perez, L., Kottke, T., Daniels, G. A., Diaz, R. M., Thompson, J., Pulido, J., Melcher, A., Vile, R. G. (2006). Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas. J. Immunol. 177: 4168-4177 [Abstract] [Full Text]